This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Americas

  1. With a recent approval from the World Health Organization, this high-quality, more affordable vaccine is poised to help more countries access protection against the top cause of deadly childhood pneumonia.
    Published: December 2019
    Type: Article
  2. This fact sheet provides an overview of pneumonia and other pneumococcal diseases, including disease burden and prevention and treatment measures. It also summarizes the pneumococcal conjugate vaccine (PCV) landscape, including the addition of Serum Institute of India, Pvt., Ltd.'s PCV (PNEUMOSIL®) to the suite of World Health Organization (WHO) prequalified PCVs. Also described are the Phase 3 clinical study results that constituted the pivotal data required for WHO prequalification.
    Published: December 2019
    Type: Resource Page
  3. You can help improve health for 1 in every 7 people on Earth.
    Published: December 2019
    Type: Article
  4. Imagine you need treatment for cervical precancer.
    Published: November 2019
    Type: Article
  5. The STANDARD™ G6PD has achieved provisional Expert Review Panel for Diagnostics (ERPD) approval, which enables procurement with Global Fund and Unitaid funds. Point-of-care diagnostics for G6PD deficiency play a critical role in supporting appropriate treatment of Plasmodium vivax malaria and efforts to eliminate the disease.
    Published: October 2019
    Type: Article
  6. PATH’s 2018 annual report describes our work to create a healthier, more equitable world.
    Published: September 2019
    Type: Article
  7. This year's annual report features our annual financial overview, PATH's leadership, list of PATH's funders and supporters and our accomplishments in 2018.
    Published: September 2019
    Type: Resource Page
  8. La Evaluación Prospectiva de País es una plataforma de evaluación que incorpora métodos mixtos diseñada para examinar el modelo de negocios del Fondo Mundial, sus inversiones y contribuciones para que los programas nacionales de VIH, tuberculosis y malaria tengan resultados positivos e impacto. La EPP se lleva a cabo en ocho países y genera evidencia oportuna para promover mejoras en losprogramas y acelerar el progreso hacia los objetivos estratégicos del Fondo Mundial 2017-2022.Este resumen presenta los resultados de Guatemala, así como los resultados sintetizados en los ocho países EPP en 2018.
    Published: July 2019
    Type: Resource Page
  9. The new, four-year Devices, Diagnostics, and Drugs to Address Women’s Needs Product Development Partnership (D3AWN PDP) is tapping into PATH’s deep PDP expertise to develop and introduce a portfolio of devices, diagnostics, and drugs to prevent or manage preeclampsia/eclampsia (PE/E) and PPH. The D3AWN PDP is advancing affordable, accessible, safe, and effective tools for sub-Saharan communities. Solutions include:Heat-stable FDT for PPH prevention: Sublingual oxytocin in heat-stable, fast dissolving tablet.Reusable, electricity-free infusion pump for the delivery of lifesaving nutrients, fluids, and medicines: RELI Delivery System.Uterine balloon tamponade for the management of PPH: Sinapi Ellavi Uterine Balloon Tamponade.Urinary dipstick test for improved diagnoses of PE/E: LifeAssay Diagnostics Test-it™ PrCr Urinalysis Dipstick Test
    Published: June 2019
    Type: Resource Page
  10. The Prospective Country Evaluation (PCE) is an embedded mixed-methods evaluation platform designed to examine the Global Fund business model, investments and contribution to disease program outcomes and impact in eight countries. The PCE generates timely evidence to support program improvements and accelerate progress towards the objectives of the Global Fund 2017-2022 Strategy.This brief presents findings synthesized across the eight PCE countries in 2018.
    Published: June 2019
    Type: Resource Page
Load more